Clinical Trial Detail

NCT ID	NCT03432741
Title	Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Recruitment	Suspended
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	Mayo Clinic
Indications	cutaneous T cell lymphoma non-Hodgkin lymphoma breast adenocarcinoma Hodgkin's lymphoma
Therapies	Carfilzomib Daratumumab Obinutuzumab Gemcitabine Trastuzumab Romidepsin Nivolumab Rituximab Belinostat Pembrolizumab
Age Groups:	adult senior